HLA-A2-restricted human CB8+ cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses

Journal of Infectious Diseases

Volumn 194, Issue 2, 2006, Pages 168-175

  Dong, Yuzhi ^a   Denny, Thomas N ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD3 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; HLA A2 ANTIGEN; INTERLEUKIN 2; LACTATE DEHYDROGENASE; SMALLPOX VACCINE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOST RESISTANCE; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMORY T LYMPHOCYTE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; ORTHOPOXVIRUS; PRIORITY JOURNAL; SMALLPOX; VACCINATION; VACCINIA VIRUS; VIRUS REPLICATION;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CONSERVED SEQUENCE; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; SMALLPOX VACCINE; TUMOR NECROSIS FACTOR-ALPHA; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 33746149648     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505224     Document Type: Article

References (36)

1. Henderson DA. The looming threat of bioterrorism. Science 1999; 283:1279-82.
2. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988:1460.
3. LeDuc JW, Becher J. Current Status of smallpox vaccine. Emerg Infect Dis 1999; 5:593-4.
4. Fenner F. The eradication of infectious diseases. S Afr Med J 1986; (Suppl):35-9.
5. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003; 37:251-71.
6. Enserink M. Bioterrorism: in search of a kinder, gentler vaccine. Science 2002; 296:1594.
7. Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004; 101:4590-5.
8. Demkowicz WE Jr, Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996; 70:2627-31.
9. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9:1131-7.
10. Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 2004; 78:7052-60.
11. Drexler I, Staib C, Kastenmuller W, et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 2003; 100: 217-22.
12. Terajima M, Cruz J, Raines G, et al. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003; 197:927-32.
13. Earl PL, Americo JL, Moss B. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol 2003; 77:10684-8.
14. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23:1094-7.
15. Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW. Preparation of cell cultures and vaccinia virus stocks. In: Ausube FM, Brent R, Kingston RE, et al., eds. Current protocols in molecular biology. Vol. 3. Boston: Wiley, 1998:16.16.1-7.
16. Pelloquin F, Lamelin JP, Lenoir GM. Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol 1986; 22:689-94.
17. Dong Y, Demaria S, Sun X, et al. HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect Immun 2004; 72:2412-5.
18. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985; 21:235-46.
19. Denny T. Cytokines: a common signaling system for cell growth, inflammation, immunity, and differentiation: In: Siegel L, Cohen I, eds. Design principles for the immune system and other distributed autonomous systems. New York: Oxford University Press, 2001:29-77.
20. Speller SA, Warren AP. Ex vivo detection and enumeration of human antigen-specific CD8+ T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining. J Immunol Methods 2002; 262:167-80.
21. Manischewitz J, King LR, Bleckwenn NA, et al. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis 2003; 188:440-8.
22. Fonteneau JF, Larsson M, Somersan S, et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 2001; 258:111-26.
23. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163-75.
24. Maecker HT, Dunn HS, Suni MA, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001; 255:27-40.
25. Chaudhri G, Panchanathan V, Buller RM, et al. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci USA 2004; 101:9057-62.
26. Reddehase MJ. The immunogenicity of human and murine cytomegaloviruses. Curr Opin Immunol 2000; 12:390-6.
27. Reddehase MJ, Koszinowski UH. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 1984; 312:369-71.
28. Howard ST, Chan YS, Smith GL. Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology 1991; 180:633-47.
29. Shchelkunov SN, Blinov VM, Resenchuk SM, et al. Analysis of the nucleotide sequence of 53 kbp from the right terminus of the genome of variola major virus strain India-1967. Virus Res 1994; 34:207-36.
30. Senkevich TG, Muravnik GL, Pozdnyakov SG, et al. Nucleotide sequence of XhoI O fragment of ectromelia virus DNA reveals significant differences from vaccinia virus. Virus Res 1993; 30:73-88.
31. Jackson RJ, Hall DF, Kerr PJ. Myxoma virus encodes an α2,3-sialyltransferase that enhances virulence. J Virol 1999; 73:2376-84.
32. Okazaki T, Pendleton CD, Lemonnier F, Berzofsky JA. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J Immunol 2003; 171:2548-55.
33. Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001; 194:833-46.
34. Neff JM, Lane JM, Pert JH, Moore R, Millar JD, Henderson DA. Complications of smallpox vaccination. I. National survey in the United States, 1963. N Engl J Med 1967; 276:125-32.
35. Weiner DB. Keeping the lock on smallpox. Nat Med 2003; 9:1115-6.
36. Edghill-Smith Y, Bray M, Whitehouse CA, et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis 2005; 191:372-81.